



Yang Fei (Autor)

Mechanistic Understanding of Enhanced Human Oral Bioavailability of Fenofibric Acid from Novel Lipid Carriers Using Semi- Physiologically Based Pharmacokinetic Model and Various Analytical Approaches Including Biorelevant Dissolution Testing

Goethe University • Institute of Pharmaceutical Technology
Prof. Dr. Jennifer B. Dressman

Yang Fei

Mechanistic Understanding of Enhanced Human Oral Bioavailability of Fenofibric Acid from Novel Lipid Carriers Using Semi-Physiologically Based Pharmacokinetic Model and Various Analytical Approaches Including Biorelevant Dissolution Testing



Cuvillier Verlag Göttingen
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/7781>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen,

Germany

Telefon: +49 (0)551 54724-0, E-Mail: info@cuvillier.de, Website: <https://cuvillier.de>



Table of contents

| | |
|--|-----|
| Acknowledgements | V |
| List of Figures..... | X |
| List of Tables..... | XIV |
| Abbreviations | XVI |
| Chapter 1. Introduction..... | 1 |
| 1.1 Lipid-based formulation – an overview | 1 |
| 1.2 Oral Lipid-based formulation with examples..... | 1 |
| 1.3 The Lipid Formulation Classification System and its application | 3 |
| 1.4 Potential advantages / disadvantages of lipid formulations | 6 |
| 1.5 Evaluation of oral lipid-based formulations..... | 7 |
| 1.5.1 Dispersion | 7 |
| 1.5.2 Digestion | 8 |
| 1.5.3 Dissolution | 10 |
| 1.6 Introduction of PBPK software applied in this research | 11 |
| 1.6.1 Overview of STELLA® software, including establishment of the PBPK model..... | 11 |
| 1.6.2 Introduction of the Simcyp simulator and its application to evaluating LBFs | 13 |
| 1.7 Introduction of the LBFs and methodology used for the present dissertation..... | 13 |
| Chapter 2. Aims of the thesis | 15 |
| 2.1 Overall aim of the thesis..... | 15 |
| 2.2 Aims of Chapter 4..... | 15 |
| 2.3 Aims of Chapter 5..... | 15 |
| Chapter 3. Materials and equipment | 16 |
| 3.1 Materials | 16 |
| 3.1.1 Chemicals..... | 16 |
| 3.1.2 Overview of fenofibrate drug substance | 18 |
| 3.2 Equipment..... | 20 |



| | |
|--|-----------|
| Chapter 4. Study of LBF No.1 – No.7 of fenofibrate | 23 |
| 4.1 Dispersion and dilution experiments | 23 |
| 4.1.1 LBFs developed at the Goethe University (No.3 – No.4) | 23 |
| 4.1.1.1 Choice of lipid-based excipients | 23 |
| 4.1.1.2 Preparation of fenofibrate lipid formulations | 24 |
| 4.1.1.3 Media preparation..... | 25 |
| 4.1.1.4 Dispersion and dilution test set-up of LBF No.2 | 27 |
| 4.1.1.5 Discussion of the dilution results of LBF No.2..... | 29 |
| 4.1.2 LBFs developed by scientists from Ireland, Switzerland, Greece and Germany (No.5 – No.7) | 30 |
| 4.1.2.1 Dilution test set-up of LBFs No.5 – No.7 | 30 |
| 4.1.2.2 Results and discussion..... | 32 |
| 4.2 Solubility experiments..... | 34 |
| 4.2.1 Literature Data | 34 |
| 4.2.2 Solubility test set-up and sample preparation | 36 |
| 4.2.3 Solution preparation and HPLC method (common to the entire thesis) | 37 |
| 4.2.4 Results and discussion of the solubility tests..... | 38 |
| 4.3 Dissolution experiments | 41 |
| 4.3.1 Dissolution testing using USP III apparatus | 41 |
| 4.3.1.1 Dissolution test set-up | 41 |
| 4.3.1.2 Results and discussion..... | 41 |
| 4.3.2 Dissolution testing using USP II apparatus | 46 |
| 4.3.2.1 Dissolution test set-up | 46 |
| 4.3.2.2 Results and discussion..... | 47 |
| 4.3.3 Dissolution experiment using the transfer model | 50 |
| 4.3.3.1 Dissolution testing set-up of the transfer model..... | 50 |
| 4.3.3.2 Results and discussion..... | 51 |
| 4.4 <i>In silico</i> simulation of plasma profiles following oral administration of LBFs | 53 |



| | |
|--|-----------|
| 4.4.1 STELLA® software approach | 53 |
| 4.4.1.1 Mathematical description of dissolution mechanisms | 53 |
| 4.4.1.2 Results and discussion..... | 57 |
| 4.4.2 Simcyp® software approach..... | 59 |
| 4.4.2.1 Description of the Simcyp® model parameters | 59 |
| 4.4.2.2 Results and discussion..... | 60 |
| Chapter 5. Study of LBF No.8 – No.11 of fenofibrate..... | 65 |
| 5.1 Preparation of LBF No.8 – No.11 | 65 |
| 5.2 Fasted state <i>IVISIVC</i> of LBF No.8 – No.11 | 66 |
| 5.2.1 Solubility of fenofibrate in biorelevant dissolution media in the presence of lipid-based excipients | 67 |
| 5.2.1.1 Solubility test set-up..... | 67 |
| 5.2.1.2 Results and discussion..... | 68 |
| 5.2.2 Dissolution studies | 69 |
| 5.2.2.1 Dissolution test set-up | 69 |
| 5.2.2.2 Results and discussion..... | 70 |
| 5.2.2.3 <i>z</i> value estimation | 73 |
| 5.2.3 STELLA® model set-up | 74 |
| 5.2.3.1 Overall description of the model map and assumptions | 74 |
| 5.2.3.2 Description of the ODEs involved | 76 |
| 5.2.3.3 Modeling of precipitation process | 77 |
| 5.2.3.4 Fenofibrate permeability estimation and STELLA® intestinal absorption model | 79 |
| 5.2.4 <i>In vivo</i> clinical study and calculation of PK parameters..... | 85 |
| 5.2.5 <i>f</i> ₂ approach and simulation outcome using STELLA® software | 87 |
| 5.2.6 Comparison of simulated and reported plasma concentration profiles..... | 94 |
| 5.2.7 Sensitivity analysis of the model parameters for simulation of the fenofibric acid plasma profiles in fasted state..... | 95 |
| 5.3 Fed state <i>IVISIVC</i> of LBF No.8 – No.11 | 99 |



| | |
|--|-----|
| 5.3.1 Media preparation | 100 |
| 5.3.2 Solubility testing and results | 101 |
| 5.3.3 Dissolution testing and results | 102 |
| 5.3.4 <i>z</i> value estimation..... | 105 |
| 5.3.5 Updated model parameters to predict the fed state plasma profiles | 105 |
| 5.3.6 Prediction of the fed state plasma profiles of fenofibric acid using STELLA® software | 106 |
| 5.3.7 Sensitivity analysis: varying model parameters for response of fenofibric acid plasma profile in the fed state..... | 111 |
| 5.3.8 Discussion of food effect and comparison of results in fasted and fed state | 113 |
| Chapter 6. Summary and outlook | 114 |
| 6.1 Summary..... | 114 |
| 6.2 Outlook | 118 |
| Chapter 7. Deutsche Zusammenfassung (German summary) | 119 |
| Appendix | 124 |
| References | 186 |
| Curriculum vitae | 195 |
| Publications and presentations | 196 |